Checkmate Pharmaceuticals Gross Profit

As of the most recent data (March 2022), CMPI shows a gross profit of $0. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $65B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CMPI's gross profit is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Checkmate Pharmaceuticals is outperforming or lagging.

The Healthcare sector average gross profit is about $65B. Checkmate Pharmaceuticals is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CMPI stacks up against individual peers as well.

Tracking CMPI's gross profit over time shows whether Checkmate Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Checkmate Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $0) with ownership activity and broader fundamentals.